Hepatocyte Growth Factor to Improve Functioning in PAD

NCTID	NCT03363165 (View at clinicaltrials.gov)
Description	HI-PAD is a placebo controlled double-blind randomized pilot clinical trial to determine whether VM202 may improve walking ability in people with lower extremity peripheral artery disease (PAD). (Show More)
Development Status	Active
Indication	Peripheral Artery Disease
Disease Ontology Term	DOID:0050830
Compound Name	ENGENSIS
Compound Alias	donaperminogene seltoplasmid, VM202
Compound Description	pCK-HGF-X7 (HGF 728, HGF723 isoforms)
Sponsor	Northwestern University
Funder Type	Other
Recruitment Status	Completed
Enrollment Count	39
Results Posted	View Results

Target Gene/Variant	HGF
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Overexpression of protective allele/gene
Route of Administration	Intramuscular (gastrocnemius)
Drug Product Type	Plasmid
Target Tissue/Cell
Delivery System	None (naked plasmid)
Vector Type
Editor Type
Dose 1	4mg (dose/leg/day) * 4 treatment days
Dose 2
Dose 3
Dose 4
Dose 5

No.of Trial Sites	1
Locations	United States